IP Library Granted Patent US 8,603,495
Granted Patent B2
US 8,603,495 · App. 12/384,201 · Granted Dec 10, 2013

Compositions and methods for biological remodeling with frozen particle compositions

Inventors: Edward S. Boyden (Cambridge, MA); Daniel B. Cook (Seattle, WA); Roderick A. Hyde (Redmond, WA); Eric C. Leuthardt (St. Louis, MO); Nathan P. Myhrvold (Medina, WA); Elizabeth A. Sweeney (Seattle, WA); Lowell L. Wood, Jr. (Bellevue, WA)
Assignee: The Invention Science Fund I, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,495
App. No.
12/384,201
Granted
Dec 10, 2013
Kind
B2
Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Claims (14)

1. A frozen particle composition, comprising:

one or more frozen particles coated with at least one neuro-muscular toxin and further include at least one biological remodeling agent including collagen and one or more of vitamin A, vitamin C, fibrin, thrombin, hyaluronic acid, hydroxylapatite, keratin, fibrinogen, hyaluronate, chitin, chitosan, methylcellulose, alginate, cellulose, polyaldehyde glucornate, Factor XIII, Factor XII, silicone, polyurethane, elastin, glycosaminoglycan, poly(alpha-hydroxyacid), or glutaraldehyde;

wherein the one or more frozen particles have at least one major dimension of approximately one micrometer or less, approximately one nanometer or less, or any value therebetween.

2. The frozen particle composition of claim 1 , wherein the at least one major dimension includes at least one of the radius, diameter, length, width, height, or perimeter.

3. The frozen particle composition of claim 1 , further including one or more extracellular matrix components.

4. The frozen particle composition of claim 1 , wherein the at least one biological remodeling agent is located in at least one cavity of the frozen particle compositions.

5. The frozen particle composition of claim 1 , further including one or more of a blood cell, chondrocyte, endothelial cell, hepatocyte, keratinocyte, myocyte, osteoblast, osteoclast, osteocyte, mesenchymal cell, stem cell, progenitor cell, or fibroblast.

6. The frozen particle composition of claim 1 , wherein the collagen includes one or more of Type I collagen, Type II collagen, Type III collagen, Type VII collagen, Type X collagen, elastin fibers, or soluble elastin.

7. The frozen particle composition of claim 1 , wherein the biological remodeling agent includes one or more of an angiogenic factor, growth factor, or cytokine.

8. The frozen particle composition of claim 1 , further including at least one of a nanoparticle, detection material, sensor, micro-syringe, or circuit.

9. The frozen particle composition of claim 1 , the frozen particles further including at least one antimicrobial agent.

10. The frozen particle composition of claim 9 , wherein the at least one antimicrobial agent includes at least one antibiotic or anti-fungal agent.

11. The frozen particle composition of claim 9 , wherein the at least one antimicrobial agent includes one or more of penicillin, cephalosporin, polymixin, sulfonamide, beta-lactam antibiotic, beta-lactamase inhibitor, enediynes, lincosamide antibiotic, nitroimidazole antibiotic, pleuromutilin antibiotic, polyketide antibiotic, polymyxin antibiotic, polypeptide antibiotic, antimicrobial peptides, quinolone antibiotic, rifamycin antibiotic, sulfonamide antibiotic, tetracycline antibiotic, aminoglycoside antibiotic, macrolide, tetracycline, cyclic lipopeptide, glycylcycline, oxazolidinone, amoxicillin, tobramycin, levofloxacin, gatifloxacin, moxifloxacin, streptomycin, oxytetracycline, chloramphenicol, or ampicillin.

12. The frozen particle composition of claim 1 , further including at least one cytotixic agent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2016
From: THE INVENTION SCIENCE FUND I LLC
To: GEARBOX, LLC
Reel/Frame 037540/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2013
From: SEARETE LLC
To: THE INVENTION SCIENCE FUND I, LLC
Reel/Frame 031545/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2009
From: BOYDEN, EDWARD S.; COOK, DANIEL B.; HYDE, RODERICK A.; LEUTHARDT, ERIC C.; MYHRVOLD, NATHAN P.; SWEENEY, ELIZABETH A.; WOOD, JR., LOWELL L.
To: SEARETE LLC
Reel/Frame 022978/0891 →
Continuity (30)
Continuation In Part 12290671 · Oct 31, 2008
Continuation In Part 12290683 · Oct 31, 2008
Continuation In Part 12290685 · Oct 31, 2008
Continuation In Part 12290686 · Oct 31, 2008
Continuation In Part 12290690 · Oct 31, 2008
Continuation In Part 12290691 · Oct 31, 2008
Continuation In Part 12290684 · Oct 31, 2008
Continuation In Part 12290670 · Oct 31, 2008
Continuation In Part 12290664 · Oct 31, 2008
Continuation In Part 12290659 · Oct 31, 2008
Continuation In Part 12290658 · Oct 31, 2008
Continuation In Part 12290665 · Oct 31, 2008
Continuation In Part 12290677 · Oct 31, 2008
Continuation In Part 12290687 · Oct 31, 2008
Continuation In Part 12290676 · Oct 31, 2008
Continuation In Part 12383264 · Mar 20, 2009
Continuation In Part 12383263 · Mar 20, 2009
Continuation In Part 12383260 · Mar 20, 2009
Continuation In Part 12383265 · Mar 20, 2009
Continuation In Part 12383851 · Mar 27, 2009
Continuation In Part 12383863 · Mar 27, 2009
Continuation In Part 12383821 · Mar 27, 2009
Continuation In Part 12383829 · Mar 27, 2009
Continuation In Part 12384202 · Mar 31, 2009
Continuation In Part 12384212 · Mar 21, 2009
Continuation In Part 12384215 · Mar 21, 2009
Continuation In Part 12384216 · Mar 31, 2009
Continuation In Part 12384218 · Mar 31, 2009
Continuation In Part 12384214 · Mar 31, 2009
Related Publication 20100111938A1 · May 6, 2010